Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Bolt Biotherapeutics
6LPCurrent price
0.59 EUR
-0.0071 EUR (-1.16%)
Last closed
0.65 USD
Company
www.boltbio.com
ISIN
US0977021049
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
24 837 682 USD
Yield for 12 month
-35.10 %
1Y
3Y
5Y
10Y
15Y
6LP
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Address: 900 Chesapeake Drive, Redwood City, CA, United States, 94063
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.75 USDP/E ratio
–Dividend Yield
–Current Year
+7 876 000 USD
Last Year
+5 729 000 USD
Current Quarter
+1 275 000 USD
Last Quarter
+5 274 000 USD
Current Year
+5 992 000 USD
Last Year
+838 000 USD
Current Quarter
+818 000 USD
Last Quarter
+4 816 000 USD
Key Figures 6LP
1 year
3 years
5 years
10 years
EBITDA
-72 229 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.41 %
PEG Ratio
–
Return On Equity TTM
-58.04 %
Wall Street Target Price
1.75 USD
Revenue TTM
11 166 000 USD
Book Value
2.24 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-11 %
Dividend Yield
–
Gross Profit TTM
1 620 000 USD
Earnings per share
-1.74 USD
Diluted Eps TTM
-1.74 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 6LP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 6LP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 6LP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
270.646
Price Sales TTM
2.2244
Enterprise Value EBITDA
0.9324
Price Book MRQ
0.2893
Financials 6LP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 6LP
For 52 weeks
0.55 USD
1.56 USD
50 Day MA
0.64 USD
Shares Short Prior Month
119 132
200 Day MA
0.88 USD
Short Ratio
0.86
Shares Short
119 446
Short Percent
0.39 %
BeatStart